Skip to main content

Compare Stocks

Date Range: 

 Silverback TherapeuticsTrillium TherapeuticsNurix TherapeuticsKinnate BiopharmaEdgewise Therapeutics
SymbolNASDAQ:SBTXTSE:TRILNASDAQ:NRIXNASDAQ:KNTENASDAQ:EWTX
Price Information
Current Price$28.49C$10.58$25.83$23.25$26.90
52 Week RangeBuyN/ABuyBuyBuy
MarketRank™
Overall Score1.70.92.01.71.8
Analysis Score3.52.03.53.53.4
Community Score4.52.54.15.03.8
Dividend Score0.00.00.00.00.0
Ownership Score0.00.01.70.01.7
Earnings & Valuation Score0.60.00.60.00.0
Analyst Ratings
Consensus RecommendationBuyN/ABuyBuyBuy
Consensus Price Target$49.50C$25.00$46.00$52.00$34.25
% Upside from Price Target73.75% upside136.29% upside78.09% upside123.66% upside27.32% upside
Trade Information
Market Cap$994.39 millionC$1.09 billion$1.15 billion$1.01 billion$1.28 billion
BetaN/AN/AN/AN/AN/A
Average Volume213,602190,399455,784189,181184,184
Sales & Book Value
Annual RevenueN/AC$148,000.00N/AN/AN/A
Price / SalesN/A7,372.90N/AN/AN/A
CashflowN/AC$2.67 per shareN/AN/AN/A
Price / CashN/A3.96N/AN/AN/A
Book ValueN/AC$2.50 per shareN/AN/AN/A
Price / BookN/A4.24N/AN/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AC($0.63)N/AN/AN/A
Trailing P/E Ratio0.00N/A0.000.000.00
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.29%N/AN/AN/A
Current RatioN/A19.34%N/AN/AN/A
Quick RatioN/A18.70%N/AN/AN/A
Ownership Information
Institutional Ownership PercentageN/AN/A81.99%N/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees54331353119
Shares Outstanding34.90 million103.14 million44.35 million43.49 million47.57 million
Next Earnings Date8/12/2021 (Estimated)8/10/2021 (Estimated)N/A7/5/2021 (Estimated)8/12/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Edgewise Therapeutics (NASDAQ:EWTX) Trading 10% Higher Edgewise Therapeutics (NASDAQ:EWTX) Trading 10% Higher
americanbankingnews.com - May 17 at 11:46 AM
Edgewise Therapeutics (NASDAQ:EWTX) Sees Strong Trading VolumeEdgewise Therapeutics (NASDAQ:EWTX) Sees Strong Trading Volume
americanbankingnews.com - May 13 at 11:54 AM
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down to $26.45Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down to $26.45
americanbankingnews.com - May 12 at 12:40 PM
Edgewise Therapeutics (NASDAQ:EWTX)  Shares Down 7.8% Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 7.8%
americanbankingnews.com - May 11 at 11:39 AM
Edgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular DystrophyEdgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular Dystrophy
finance.yahoo.com - May 4 at 11:20 AM
Cricut (NASDAQ:EWTX) Sees Large Volume IncreaseCricut (NASDAQ:EWTX) Sees Large Volume Increase
americanbankingnews.com - April 29 at 2:50 PM
Cricut (NASDAQ:EWTX) Stock Price Up 7.4%Cricut (NASDAQ:EWTX) Stock Price Up 7.4%
americanbankingnews.com - April 28 at 3:29 PM
Cricuts (NASDAQ:EWTX) Quiet Period Set To Expire  on May 5thCricut's (NASDAQ:EWTX) Quiet Period Set To Expire on May 5th
americanbankingnews.com - April 28 at 1:24 AM
Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical OfficerEdgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical Officer
finance.yahoo.com - April 27 at 1:28 PM
Cricut (NASDAQ:EWTX) Shares Gap Down to $27.54Cricut (NASDAQ:EWTX) Shares Gap Down to $27.54
americanbankingnews.com - April 26 at 1:46 PM
SVB Leerink Initiates Coverage on Cricut (NASDAQ:EWTX)SVB Leerink Initiates Coverage on Cricut (NASDAQ:EWTX)
americanbankingnews.com - April 26 at 11:32 AM
Cricut (NASDAQ:EWTX) Research Coverage Started at WedbushCricut (NASDAQ:EWTX) Research Coverage Started at Wedbush
americanbankingnews.com - April 26 at 11:32 AM
Cricut (NASDAQ:EWTX) Now Covered by Analysts at JPMorgan Chase & Co.Cricut (NASDAQ:EWTX) Now Covered by Analysts at JPMorgan Chase & Co.
americanbankingnews.com - April 26 at 10:58 AM
Cricut (NASDAQ:EWTX) Now Covered by Analysts at The Goldman Sachs GroupCricut (NASDAQ:EWTX) Now Covered by Analysts at The Goldman Sachs Group
americanbankingnews.com - April 26 at 8:36 AM
Cricut and Siyata Mobile among tech gainers for the day; Intrusion and Canaan among losersCricut and Siyata Mobile among tech gainers for the day; Intrusion and Canaan among losers
seekingalpha.com - April 19 at 3:54 PM
Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesEdgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - April 2 at 8:35 AM
DateCompanyBrokerageAction
5/17/2021Silverback TherapeuticsSVB LeerinkLower Price Target
3/30/2021Silverback TherapeuticsStifel NicolausBoost Price Target
3/30/2021Silverback TherapeuticsThe Goldman Sachs GroupBoost Price Target
12/29/2020Silverback TherapeuticsHC WainwrightInitiated Coverage
12/9/2020Trillium TherapeuticsJonestradingBoost Price Target
5/6/2021Nurix TherapeuticsRoyal Bank of CanadaInitiated Coverage
4/20/2021Nurix TherapeuticsBerenberg BankInitiated Coverage
2/17/2021Nurix TherapeuticsNeedham & Company LLCReiterated Rating
2/17/2021Nurix TherapeuticsPiper SandlerBoost Price Target
1/29/2021Nurix TherapeuticsJPMorgan Chase & Co.Boost Price Target
11/18/2020Nurix TherapeuticsRobert W. BairdInitiated Coverage
12/28/2020Kinnate BiopharmaWedbushInitiated Coverage
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.